BioLineRx (BLRX) director details extensive stock option grants

Rhea-AI Filing Summary

BioLineRx Ltd. director Sandra Panem filed an initial ownership report showing multiple employee stock options to buy Ordinary Shares. The options cover blocks such as 199,800 shares at an exercise price of $0.356 and 1,080,000 shares at $0.085, with expirations between 2026 and 2034.

Footnotes state that earlier grants from 2016 through 2024 are fully vested, while an October 1, 2024 grant left 856,200 options vested at appointment and 1,198,800 options scheduled to vest in seven equal quarterly installments, subject to her continued service.

Insider Trade Summary

10 transactions reported

Mixed 10 txns

Insider PANEM SANDRA

Role Director

Type	Security	Shares	Price	Value
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 49,800 shares (Direct)

Footnotes (1)

1. Options granted under the 2003 Amended and Restated Share Incentive Plan. The grant date of this grant is July 5, 2016. This option grant is fully vested as of this date. The grant date of this grant is July 5, 2017. This option grant is fully vested as of this date. The grant date of this grant is July 5, 2018. This option grant is fully vested as of this date. The grant date of this grant is July 2, 2019. This option grant is fully vested as of this date. The grant date of this grant is July 2, 2020. This option grant is fully vested as of this date. The grant date of this grant is July 2, 2021. This option grant is fully vested as of this date. The grant date of this grant is July 3, 2022. This option grant is fully vested as of this date. The grant date of this grant is July 3, 2023. This option grant is fully vested as of this date. The grant date of this grant is July 3, 2024. This option grant is fully vested as of this date. The grant date of this grant is October 1, 2024. As of this date, 856,200 of the options were vested as of the date of appointment. The remaining 1,198,800 options will vest in 7 equal quarterly installments, subject to the Reporting Person's continued service to the Issuer as of each vesting date.

Key Figures

Option block: 199,800 shares at $0.356 Option block: 79,800 shares at $0.369 Option block: 1,080,000 shares at $0.085 +4 more

7 metrics

Option block 199,800 shares at $0.356 Employee stock option, expiration July 2, 2029

Option block 79,800 shares at $0.369 Employee stock option, expiration July 2, 2030

Option block 1,080,000 shares at $0.085 Employee stock option, expiration July 3, 2032

Option block 360,000 shares at $0.081 Employee stock option, expiration July 3, 2033

Option block 2,055,000 shares at $0.052 Employee stock option, expiration August 14, 2034

Older grant 49,800 shares at $0.837 Employee stock option, expiration July 5, 2026

Staged vesting portion 1,198,800 options From October 1, 2024 grant, vesting in 7 quarterly installments

Key Terms

Employee Stock Option (Right to Buy), Ordinary Shares, 2003 Amended and Restated Share Incentive Plan, grant date, +2 more

6 terms

Employee Stock Option (Right to Buy) financial

"security_title: "Employee Stock Option (Right to Buy)""

Ordinary Shares financial

"underlying_security_title: "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

2003 Amended and Restated Share Incentive Plan financial

"Options granted under the 2003 Amended and Restated Share Incentive Plan."

grant date financial

"The grant date of this grant is July 5, 2016."

The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

vested financial

"This option grant is fully vested as of this date."

vesting date financial

"will vest in 7 equal quarterly installments, subject to the Reporting Person's continued service to the Issuer as of each vesting date."

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

PANEM SANDRA

(Last) (First) (Middle)

C/O BIOLINERX LTD.

2 HAMA'AYAN STREET

(Street)

MODII'N 7177871

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
BioLineRx Ltd. [ BLRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)(1)(2)	10/05/2016	07/05/2026	Ordinary Shares	49,800	$0.837	D
Employee Stock Option (Right to Buy)(1)(3)	10/05/2017	07/05/2027	Ordinary Shares	19,800	$0.92	D
Employee Stock Option (Right to Buy)(1)(4)	10/05/2018	07/05/2028	Ordinary Shares	19,800	$0.894	D
Employee Stock Option (Right to Buy)(1)(5)	10/02/2019	07/02/2029	Ordinary Shares	199,800	$0.356	D
Employee Stock Option (Right to Buy)(1)(6)	10/02/2020	07/02/2030	Ordinary Shares	79,800	$0.369	D
Employee Stock Option (Right to Buy)(1)(7)	10/02/2021	07/02/2031	Ordinary Shares	79,800	$0.388	D
Employee Stock Option (Right to Buy)(1)(8)	10/03/2022	07/03/2032	Ordinary Shares	1,080,000	$0.085	D
Employee Stock Option (Right to Buy)(1)(9)	10/03/2023	07/03/2033	Ordinary Shares	360,000	$0.081	D
Employee Stock Option (Right to Buy)(10)	10/03/2024	07/03/2032	Ordinary Shares	360,000	$0.085	D
Employee Stock Option (Right to Buy)(11)	01/01/2025	08/14/2034	Ordinary Shares	2,055,000	$0.052	D

Explanation of Responses:

1. Options granted under the 2003 Amended and Restated Share Incentive Plan.

2. The grant date of this grant is July 5, 2016. This option grant is fully vested as of this date.

3. The grant date of this grant is July 5, 2017. This option grant is fully vested as of this date.

4. The grant date of this grant is July 5, 2018. This option grant is fully vested as of this date.

5. The grant date of this grant is July 2, 2019. This option grant is fully vested as of this date.

6. The grant date of this grant is July 2, 2020. This option grant is fully vested as of this date.

7. The grant date of this grant is July 2, 2021. This option grant is fully vested as of this date.

8. The grant date of this grant is July 3, 2022. This option grant is fully vested as of this date.

9. The grant date of this grant is July 3, 2023. This option grant is fully vested as of this date.

10. The grant date of this grant is July 3, 2024. This option grant is fully vested as of this date.

11. The grant date of this grant is October 1, 2024. As of this date, 856,200 of the options were vested as of the date of appointment. The remaining 1,198,800 options will vest in 7 equal quarterly installments, subject to the Reporting Person's continued service to the Issuer as of each vesting date.

	/s/ Sandra Panem	03/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does BioLineRx (BLRX) director Sandra Panem report in this Form 3?

Sandra Panem reports her existing holdings of employee stock options to acquire BioLineRx Ordinary Shares. These options span several grants with different exercise prices and expiration dates, reflecting accumulated equity-based compensation rather than new open-market share purchases or sales.

How many BioLineRx shares are covered by Sandra Panem’s largest option grants?

Some of the largest reported grants cover 1,080,000 underlying Ordinary Shares at an exercise price of $0.085 and 2,055,000 underlying Ordinary Shares at $0.052. Smaller grants range from 19,800 to 199,800 underlying shares at higher exercise prices closer to $0.90.

What are the exercise prices on Sandra Panem’s BioLineRx stock options?

Reported exercise prices range from $0.052 to $0.920 per Ordinary Share. Larger, more recent grants carry lower exercise prices such as $0.052, $0.081, and $0.085, while older grants have higher prices, including $0.837, $0.894, and $0.920 per share.

When do Sandra Panem’s BioLineRx stock options expire?

The options have staggered expiration dates between July 5, 2026, and August 14, 2034. Earlier higher-priced grants expire in 2026, 2027, and 2028, while larger, lower-priced grants extend through 2029, 2030, 2031, 2032, 2033, and 2034, providing long-dated potential equity exposure.

Are Sandra Panem’s BioLineRx option grants fully vested?

Footnotes state that grants dated July 5, 2016 through July 3, 2024 are fully vested. For the October 1, 2024 grant, 856,200 options were vested at appointment, and 1,198,800 additional options will vest in seven equal quarterly installments, contingent on continued service.

Under which plan were Sandra Panem’s BioLineRx options granted?

The options were granted under BioLineRx’s 2003 Amended and Restated Share Incentive Plan. This plan governs the terms of equity compensation, including grant dates, vesting schedules, exercise prices, and expiration dates for the employee stock options reported in this Form 3 filing.